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Objective: Plasma phospholipid transfer protein (PLTP) plays a key role in lipoprotein metabolism. Its
exact function in the development of atherosclerosis is still under debate however. We studied the effect
of elevated PLTP expression in one of the most commonly used models of atherosclerosis, the ApoE
deﬁcient mouse.
Methods: Experiment 1: Plasma PLTP activity, total cholesterol, HDL cholesterol and atherosclerosis
development was measured in ApoE deﬁcient mice with or without elevated expression of PLTP.
Experiment 2: The same parameters were measured in ApoE deﬁcient mice after bone marrow trans-
plantation from wild type mice or mice with elevated PLTP expression. Experiment 3: Similar to
experiment 2, but using donor mice with an ApoE deﬁcient background.
Results: Experiment 1: ApoE deﬁcient mice have more than two times more atherosclerosis when
overexpressing PLTP and a strongly decreased plasma level of HDL. Experiment 2: Bone marrow trans-
plantation with ApoE proﬁcient cells results in a strong reduction of plasma cholesterol in ApoE deﬁcient
acceptor mice. Still, elevated PLTP in bone marrow derived cells evoke a reduction of HDL cholesterol and
increased atherosclerosis. Experiment 3: Bone marrow transplantation with ApoE deﬁcient cells results
in much higher cholesterol levels, but here too HDL cholesterol levels are reduced and atherosclerosis
increased.
Conclusion: In all the models with ApoE deﬁciency, elevated PLTP expression causes higher levels of diet-
induced atherosclerosis coinciding with decreased plasma levels of HDL cholesterol.
 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license. 1. Introduction
The role of plasma phospholipid transfer protein (PLTP) in
health and disease has been investigated for many years by several
research groups around the world. Still, pivotal questions remain
unanswered [1].
PLTP is present in the plasma of all investigated mammalian
species, which suggests an essential function. There are no reports
on a naturally occurring lack of PLTP activity in humans [2].
Nevertheless, PLTP deﬁciency that has been induced by gene tar-
geting in mice, does not seem to have any gross abnormalities [3,4].
However, the lipid transfer activity of PLTP, which is not rigidly
restricted to phospholipids [1], clearly affects plasma lipoproteins.
Therefore, a possible relation with the development ofology & Genetics, Erasmus
Rotterdam, The Netherlands.
rom).
 the Elsevier OA license. atherosclerosis has been extensively investigated, both in patients
and in experimental animals.
In humans, changes in PLTP activity in plasma have been asso-
ciated with several conditions that are also related to an increased
risk of atherosclerosis development. An increased PLTP activity has
been reported in individuals with diabetes mellitus (both type 1
and type 2), metabolic syndrome and obesitas [5e8]. In addition,
some studies have shown a relationship between a higher PLTP
activity and an increased risk of coronary artery disease [9,10]. More
recently PLTP was identiﬁed as a marker for cardiovascular disease
in a large genetic study [11]. However, there is still debate on the
mechanism by which PLTP can be atherogenic in humans. Well-
controlled studies in experimental animals maybe helpful to shed
more light on this issue.
PLTP deﬁcient mice have a lowered susceptibility for athero-
sclerosis, while PLTP transgenic mice have more atherosclerosis
[4,12]. However, animal studies have not been unequivocal either,
because both PLTP deﬁcient and PLTP transgenicmice have lowered
HDL levels [4,12]. Most likely, the mechanism involved is different
in these two models: in PLTP deﬁcient mice the decreased level of
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very low density lipoproteins (VLDL) by the liver, maybe further
deteriorated by a decreased lipoprotein susceptibility to oxidation
and reduced cholesterol absorption [2], while in PLTP transgenic
mice, the lowered HDL level has been held responsible [12,13]. Also,
conﬂicting results have been reported in bone marrow trans-
plantation studies using PLTP deﬁcient mice, aiming at studying the
role of bone marrow derived cells in the process of atherogenesis.
In previous work from our group, we invariably found that
elevated PLTP expression in transgenic mice, resulting in increased
PLTP activity in plasma, causes an increased susceptibility for diet-
induced atherosclerosis. We also performed bone marrow trans-
plantation experiments and found a similar relationship between
PLTPactivity and atherosclerosis [13]. However, all of our studies have
been performed in mice that were susceptible to atherosclerosis
because of LDL-receptor deﬁciency. In PLTP deﬁcient mice, the
outcome of atherosclerosis susceptibility studies was shown to be
dependent on the mouse model used: the results in LDL-receptor
deﬁcient mice appeared to differ from the results obtained in apoli-
poprotein (apo) E deﬁcient or apoB transgenic mice [4]. Therefore, in
the present set of experiments, we crossed our PLTP transgenic mice
with apo E deﬁcientmice, the other commonly usedmousemodel for
atherosclerosis development. We also performed bone marrow
transplantation studieswith theseanimals to producemore clarity on
the atherogenic potential of PLTP in bone marrow derived cells.
2. Materials and methods
2.1. Mice
ApoE deﬁcient (ApoE-KO) mice were obtained from the Jackson
Laboratory (Bar Harbor, ME) and are in C57BL6/J background. PLTP
transgenic (PLTPtg) micewere generated in our laboratory and have
been described before [12]. The animals used in the present study
are derived from the P4 line and were crossed for more than 15
generations into C57BL6/J background. The animals express the
human PLTP gene driven by the autologous human PLTP promoter.
Animals received water and food ad libitum. Food consisted of
regular chow or, for the atherosclerosis experiments, of high fat
high cholesterol diet containing 40% (w/w) sucrose, 15% (w/w)
cocoa butter, and 0.25% (w/w) cholesterol (diet W; Hope Farms,
Woerden, The Netherlands). All animals used for experiments were
male. Groups consisted of 9 animals. There were three groups of
mice in the experiments described here: group 1 consisted of
PLTPtg and PLTPtg/ApoE-KO mice that were subjected to athero-
sclerosis experiments without bone marrow transplantations (see
below), group 2 consisted of animals that were subjected to bone
marrow transplantation experiments in which the recipient mice
were ApoE-KO mice while the donor mice were either wild type
control mice or PLTPtg mice (i.e., in both cases ApoE proﬁcient),
while group 3 consisted of animals that were subjected to bone
marrow transplantation experiments in which the recipient mice
were ApoE-KO mice while the donor mice were either also ApoE-
KO mice or ApoE-KO/PLTPtg mice (i.e., in both cases ApoE deﬁ-
cient). All of the procedures in this study were approved by the
committee on animals experiments and are in accordance with
national and institutional guidelines.
2.2. Bone marrow transplantation experiments
Experiments were performed essentially as described before
[13]. Acceptor mice received a split dose of in total 900 rad of
g-irradiation from a 137Cs source with an interval of 3 h. Bone
marrow transplants were derived from donor mice by collecting
cells from tibia and femurs. Five million cells were injected peranimal via the tail vein. Acceptor mice were fed chow diet and
water containing 0.16% Neomycin. Starting at nine weeks after
transplantation, animals received the atherogenic diet for another
21 weeks (group 2) or eight weeks (group 3), before the level of
atherosclerosis was determined.
2.3. Atherosclerosis
Animals were sacriﬁced and in situ ﬁxation was performed by
perfusing 4% (v/v) formaldehyde via the heart. Atherosclerosis was
quantiﬁed in sections from the aortic root [12,13].
2.4. Plasma PLTP activity, lipids and lipoproteins
Quantiﬁcation of the activity of plasma PLTP, levels of triglyc-
erides, cholesterol and lipoproteins in plasma was performed as
described before [12,13].
2.5. Statistics
All values are expressed asmean S.E. Statistical analyses are by
ManneWhitney tests to compare groups and paired t-tests to
compare time points within a group. Correlations are tested by
linear regression. All tests were performed in Stata 12.0 (College
Station, TX USA).
3. Results
In the ﬁrst set of experiments, we studied the impact of elevated
expression of PLTP on diet-induced atherosclerosis inmice deﬁcient
for apoE. As shown in Fig. 1A, PLTP activity in plasma is about 3-fold
higher in PLTP transgenic mice (PLTPtg) than in control mice. After
feeding the animals a high fat, high cholesterol (HFHC) diet for 8
weeks, PLTP activity is approximately 40% higher in both groups.
Plasma triglyceride levels are moderately increased in PLTPtg mice,
while the HFHC diet resulted in a decrease (Fig. 1C). Total and non-
HDL plasma cholesterol is 40% lower in PLTPtg animals than in
controls, both before and after feeding the animals the HFHC diet,
while HDL cholesterol is extremely low in PLTPtg animals and is not
affected by the diet regime (Fig.1B, D, E). The level of atherosclerosis
is considerably higher in PLTPtg mice (approximately 2.5-fold;
Fig.1F, G, H), in spite of the lowered level of total plasma cholesterol.
Probably the very low level of HDL cholesterol is causing this effect.
Subsequently, we performed a series of experiments with bone
marrow transplantations in which we used PLTPtg or wild type
control mice, so both with apoE expression, as donors and apoE
deﬁcient mice as acceptors. We observed that plasma PLTP activity
was substantially increased after transplantation with bone
marrow from PLTPtg mice, as compared to animals transplanted
with bone marrow from wild type mice (Fig. 2A). This effect was
found both before and after feeding themice an HFHC diet. The diet
itself also induced an increase in PLTP activity, as was observed in
apoE deﬁcient mice (Fig.1) and in other mice in previous work from
our group [13]. Triglycerides, total plasma cholesterol and non-HDL
cholesterol are strongly decreased after 9 weeks following bone
marrow transplantation (Fig. 2BeD), which is very likely caused by
the introduction of apo E by the bone marrow derived cells. The
HFHC diet does not affect plasma triglycerides, nor is there any
difference in plasma triglycerides between animals transplanted
with wild type cells or with PLTPtg cells (Fig. 2C). After the diet
period there is again a rise in total cholesterol, but this does not
result in a difference in plasma cholesterol between the group
transplanted with wild type cells and the group transplanted with
PLTPtg cells (Fig. 2B) and only in a small difference in non-HDL
cholesterol (Fig. 2D). In contrast, HDL cholesterol is strongly
Fig. 1. Plasma PLTP activity levels (A), total cholesterol (B), triglycerides (C), non-HDL cholesterol (D), HDL cholesterol (E) and atherosclerotic lesion size (F) were measured in apoE
deﬁcient mice (E-KO) and in PLTP transgenic mice in an apoE deﬁcient background (E-KO/PLTPtg) before (white bars) and after 8 weeks of a high fat, high cholesterol diet (blue
bars). *p < 0.05, ***p < 0.001 versus 0 weeks (same genotype) ###p < 0.001 versus apoE deﬁcient mice (same diet). Representative photomicrographs of atherosclerotic lesions are
provided in G (E-KO) and H (E-KO/PLTPtg). See Methods for details, where this group is referred to as “group 1”. (The reader is referred to the web version of this article for full color
ﬁgures)
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marrow cells (Fig. 2E), while atherosclerosis is markedly enhanced
(by a factor of 5) in this group (Fig. 2F, G, H). So, also in this set of
experiments, elevated PLTP appears to result in a strong induction
of diet-induced atherosclerosis that coincides with lowered levels
of plasma HDL.
Because of the strong effect of apoE that was reintroduced in the
set of experiments described above, we decided to perform a third
set of experiments with a similar setup but with apoE deﬁcient
donor mice. Here too, PLTP activity was increased following
transplantation with PLTPtg bone marrow cells (Fig. 3A). Plasma
triglycerides are not affected by either diet or genotype of the bone
marrow cells used for transplantation (Fig. 3C). On a chow diet,
there are no, or only marginal, differences in total and non-HDL
plasma cholesterol between the group that was transplanted with
control cells (ApoE-KO) or with cells with the PLTP transgene
(PLTPtg/ApoE-KO) (Fig. 3B, D). HDL cholesterol is lower in the mice
transplanted with PLTP expressing cells (Fig. 3E). After feeding the
animals the high fat, high cholesterol diet for 8 weeks, total and
non-HDL cholesterol is decreased in the PLTPtg/ApoE-KO group and
HDL cholesterol even more so. Atherosclerosis was about 75%
higher in the animals transplanted with PTLP expressing cells
(Fig. 3F, G, H).
4. Discussion
The most important results of the present study are: 1) As
previously demonstrated for low density lipoprotein receptor
deﬁcient mice, in apoE deﬁcient mice an elevated expression ofPLTP results in an increased PLTP activity in plasma, a decreased
total plasma cholesterol (which is mainly caused by a decrease in
non-HDL cholesterol) and a strongly decreased HDL cholesterol
level in plasma. This again results in increased atherosclerosis. 2)
After transplantation with bone marrow from mice with elevated
PLTP expression and a normal expression of apoE as donors and
apoE deﬁcient mice as acceptors, the total cholesterol level is
strongly decreased, despite the HFHC diet. On the other hand, HDL
cholesterol is much lower and atherosclerosis substantially
increased compared with animals that received wild type bone
marrow cells. 3) After transplantationwith bonemarrow frommice
with elevated PLTP expression but with deﬁcient apoE expression,
the plasma levels of total cholesterol are strongly elevated after
feeding the animals a HFHC diet, although to a lesser extent than in
mice that were submitted to transplantation with bone marrow
from mice with normal (i.e., wild type) PLTP expression but with
deﬁcient apoE expression. HDL cholesterol again is strongly
decreased and atherosclerosis is 75% higher in animals that
received cells with increased PLTP expression. In conclusion: in all
the models with apoE deﬁciency, elevated PLTP expression causes
higher levels of diet-induced atherosclerosis coinciding with
decreased plasma levels of HDL cholesterol.
Obviously, coinciding observations do not constitute proof of
a causal relationship. It would be interesting to study if a statistically
signiﬁcant correlation exists between the levels of plasma PLTP
activity, HDL cholesterol and atherosclerotic plaque size within
experimental groups. Because of the strong variation between
individual animals, much larger groups would be needed, however.
If animals with and without elevated PLTP expression, or animals
Fig. 3. Plasma PLTP activity levels (A), total cholesterol (B), triglycerides (C), non-HDL cholesterol (D), HDL cholesterol (E) and atherosclerotic lesion size (F) were measured in mice
at the moment of the start of the bone marrow transplantation (white bars), after 9 weeks or recovery following the bone marrow transplantation procedure (yellow bars) and after
8 weeks of feeding the animals a high fat, high cholesterol diet following the nine weeks recovery period (black bars). Donor animals were either apoE deﬁcient (ApoE-KO) or apoE
deﬁcient/PLTP transgenic mice (PLTPtg/ApoE-KO), recipient mice were apoE deﬁcient animals (ApoE-KO). *p < 0.05, **p < 0.01, ***p < 0.001 versus ApoE-KO/ ApoE-KO mice (same
time point). Representative photomicrographs of atherosclerotic lesions are provided in G (ApoE-KO/ ApoE-KO) and H (PLTPtg/ApoE-KO/ ApoE-KO). See Methods for details,
where this group is referred to as “group 3”. (The reader is referred to the web version of this article for full color ﬁgures)
Fig. 2. Plasma PLTP activity levels (A), total cholesterol (B), triglycerides (C), non-HDL cholesterol (D), HDL cholesterol (E) and atherosclerotic lesion size (F) were measured in mice
at the moment of the start of the bone marrow transplantation (white bars), after 9 weeks or recovery following the bone marrow transplantation procedure (yellow bars) and after
21 weeks of feeding the animals a high fat, high cholesterol diet following the nine weeks recovery period (black bars). Donor animals were either wild type (wt) or homozygous
PLTP transgenic mice (PLTPtg hozy). Recipient mice were apoE deﬁcient animals (ApoE-KO). ***p < 0.001 versus wild type/ apoE deﬁcient mice (same time point). Representative
photomicrographs of atherosclerotic lesions are provided in G (wild type/ ApoE-KO) and H (PLTPtg hozy/ ApoE-KO). See Methods for details, where this group is referred to as
“group 2”. (The reader is referred to the web version of this article for full color ﬁgures)
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taken together, as they have been compared in Figs. 1e3 respec-
tively, strong correlations between these parameters can be found,
but not in the separate groups, even though tendencies are surely
present in several of these groups (results not shown).
The reintroduction of apoE, even if only in bone marrow derived
cells, has strong effects on plasma lipids and the susceptibility to
diet-induced atherosclerosis. This has been demonstrated previ-
ously [14,15], leading to the conclusion that apoE has critical roles
in the protection against atherosclerosis. The mechanism appears
to be complex, as there are several functions of apoE that might
contribute to its anti-atherogenic properties. These include the role
of apoE in reverse cholesterol transport [16], as well as its anti-
inﬂammatory, antiproliferative and immunomodulatory proper-
ties [17]. The present study shows that PLTP from bone marrow
derived cells has its effects on HDL and atherosclerosis both in the
absence and presence of macrophage apoE, indicating that these
effects are not apoE dependent.
The expression or deﬁciency of either apoE or PLTP in bone
marrow derived cells both have strong effects on lipoprotein levels
in the plasma compartment. Both apoE and PLTP are secreted by
macrophages, which probably explains these effects. In the case of
apoE, the effects are unexpectedly high because more than 90% of
ApoE is derived from the liver [18] and thereforemacrophages have
only a modest contribution to the normal levels of plasma apoE. It
has been reported in apoE deﬁcient mice that have been recon-
stituted with apoE expressing bone marrow cells, plasma levels of
apoE are approximately 10% of the normal values [18]. Additional
studies have shown that even (much) lower levels of plasma apoE
still have clear effects on plasma lipids, suggesting that there is an
excess of plasma apoE under normal conditions [19,20]. In the case
of PLTP, we previously showed PLTP production and secretion by
macrophages from both wild type and PLTPtg mice [13]. In the
present study, plasma PLTP activity in animals transplanted with
bonemarrow from PLTPtgmicewas 50e80% higher than in animals
transplanted with wild type bone marrow. This modestly elevated
PLTP activity caused profound effects on plasma total cholesterol
and HDL cholesterol levels. Apparently, the elevation of PLTP in this
model exceeds a threshold level. It was shown in a previous study
that 30% elevation of PLTP did not result in any signiﬁcant effects on
plasma lipoproteins [21].
PLTP overexpression in apoE deﬁcient mice was also studied by
Yang et al. [22] in an adenovirus-associated virus mediated system.
In this model of acute overexpression, increased atherosclerosis
was also found to coincide with decreased HDL levels in plasma.
They did not observe any differences in non-HDL cholesterol levels,
but did ﬁnd an increase in lipoprotein oxidizability. In our study we
did not test the antioxidative protection of apolipoprotein B (apoB)
containing lipoproteins, because we observed decreased levels of
non-HDL cholesterol. However, the possibility that even the
decreased levels of apoB containing lipoproteins are more athero-
genic because their antioxidative protection capabilities are
dramatically decreased, cannot be excluded.
In a recent study, the effect of liver-speciﬁc PLTP expression in
a PLTP deﬁcient background was examined [23]. In this model,
a strong increase in non-HDL cholesterol was observed without any
effect on HDL cholesterol. This work shows independent effects by
PLTP on apoB containing lipoproteins and HDL, demonstrating the
complexity of the role of PLTP in lipid and lipoprotein metabolism.
The relative contribution of these effects to atherogenesis might
well be dependent on the experimental model used.
The effect of PLTP in bone marrow derived cells on the devel-
opment of atherosclerosis has also been studied in PLTP deﬁcient
mice by two independent groups [24,25]. Surprisingly, these
studies showed strikingly different outcomes. Valenta et al. foundthat PLTP deﬁciency in macrophages results in higher levels of diet-
induced atherosclerosis, while Vikstedt et al. reported decreased
atherosclerosis. It is not easy to ﬁnd a satisfactory solution for this
apparent discrepancy, although there are several differences in the
experimental setup of both studies. Some of these are probably
more relevant than others, as we discussed before [13]. Already in
an early stage, PLTP deﬁcient mice have yielded puzzling results:
even though HDL levels were decreased in PLTP knockout mice,
diet-induced atherosclerosis was lower [4]. This was initially
explained by a reduction of apoB containing lipoproteins. However,
this effect was observed in apoE knockout mice, but not in LDLR
knockout mice. It is therefore of interest to see that the effects of
elevated PLTP expression as described in the previous and in the
present studies from our group, are observed both in LDLR
knockout mice and in apoE knockout mice.
A new animal model was recently developed to study the role of
PLTP in atherosclerosis [26]. In these animals, PLTP transgenic
rabbits, the human PLTP cDNA was driven by the human eF1-
a promoter. This resulted in a widespread tissue expression and
a marked elevation of plasma PLTP activity. Importantly, diet-
induced atherosclerosis was increased in these animals as
compared to nontransgenic littermates. So, this new model
provides further evidence for a pro-atherogenic potential of PLTP.
The role of PLTP in atherosclerosis in humans has long been
under debate [27]. Higher plasma PLTP levelswere found in humans
with conditions associated with an increased risk for artery disease,
including obesitas and diabetes mellitus [2,8]. Variation in plasma
PLTP activity in humans is at least in part caused by genetic factors
[28]. Recently, a large number of individuals from ﬁve studies were
analyzed byVergeer et al. [11]. They investigated genetic variation at
the PLTP locus and found an associationwith decreased plasma PLTP
activity and a reduced risk of cardiovascular disease. Although the
effect is probably too small to allow predicting cardiovascular
disease based on PLTP SNPs, PLTP might prove an interesting target
for (pharmacological) inhibition [11,29,30]. Our present and earlier
ﬁndings in mice substantiate this notion.
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